untitled h1
14. quality control and quality

The investigator will permit study-related monitoring, audits, and inspections by the IRB, government regulatory bodies, and institution's compliance and quality assurance groups of all study related documents (e.g. source documents, regulatory documents, data collection instruments, study data etc.). The investigator will ensure the capability for inspections of applicable study-related facilities (e.g. pharmacy, diagnostic laboratory, etc.). Participation as an investigator in this study implies acceptance of potential inspection by government regulatory authorities and applicable Ochsner compliance and quality assurance offices.  
15. **PUBLICATIONS**
The results of this study may be published in a medical publication, journal, or may be used for teaching purposes. Additionally, this study and its results may be submitted for inclusion in all appropriate health authority study registries, as well as publication on health authority study registry websites, as required by local health authority regulations. Selection of first authorship will be based on several considerations, including, but not limited to study participation, contribution to the protocol development, and analysis and input into the manuscript, related abstracts, and presentations in a study.  
16. **REFERENCES**
Albiges, L., F. Chamming's, B. Duclos, M. Stern, R. J. Motzer, A. Ravaud and P. Camus (2012). "Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma." Ann Oncol 23(8): 1943-1953.  
Baselga, J., M. Campone, M. Piccart, H. A. Burris, 3rd, H. S. Rugo, T. Sahmoud, S. Noguchi, M. Gnant, K. I. Pritchard, F. Lebrun, J. T. Beck, Y. Ito, D. Yardley, I. Deleu, A. Perez, T. Bachelot, L. Vittori, Z. Xu, P. Mukhopadhyay, D. Lebwohl and G. N. Hortobagyi (2012). "Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer." N Engl J Med 366(6): 520-529. Chan, D. L., E. Segelov and S. Singh (2017). "Everolimus in the management of metastatic neuroendocrine tumours." Therap Adv Gastroenterol 10(1): 132-141. Cirstea, D., T. Hideshima, S. Rodig, L. Santo, S. Pozzi, S. Vallet, H. Ikeda, G. Perrone, G. Gorgun, K. Patel, N. Desai, P. Sportelli, S. Kapoor, S. Vali, S. Mukherjee, N. C. Munshi, K. C. Anderson and N. Raje (2010). "Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma." Mol Cancer Ther 9(4): 963-975. de Oliveira, M. A., E. M. F. Martins, Q. Wang, S. Sonis, G. Demetri, S. George, J. Butrynski and N. S. Treister (2011). "Clinical presentation and management of mTOR inhibitor-associated stomatitis." Oral Oncol 47(10): 998-1003.  
De, T., V. Trieu, Z. Yim, J. Cordia, A. Yang, B. Beals, S. Ci, L. Louie and N. Desai (2007). Nanoparticle albumin-bound (nab) rapamycin as an anticancer agent. Proceedings of the 98th American Association for Cancer Research Annual Meeting (AACR), Los Angeles CA, AACR. Desai, N., O. D'Cruz and V. Trieu (2009). Potent antitumor effects of nab-rapamycin (ABI-009) in combination with kinase inhibitors erlotinib and perifosine. Proceedings of the 100th American Association for Cancer Research Annual Meeting (AACR), Denver CO, AACR. Desai, N., V. Trieu, Z. Yao, L. Louie, S. Ci, A. Yang, C. Tao, T. De, B. Beals, D. Dykes, P. Noker, R. Yao, E. Labao, M. Hawkins and P. Soon-Shiong (2006). "Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel." Clin Cancer Res 12(4): 13171324. Dowling, R. J., I. Topisirovic, B. D. Fonseca and N. Sonenberg (2010). "Dissecting the role of mTOR: lessons from mTOR inhibitors." Biochim Biophys Acta **1804**(3): 433-439. Fasolo, A. and C. Sessa (2012). "Targeting mTOR pathways in human malignancies." Curr Pharm Des 18(19): 2766-2777. Gonzalez-Angulo, A. M., F. Meric-Bernstam, S. Chawla, G. Falchook, D. Hong, A. Akcakanat, H. Chen, A. Naing, S. Fu, J. Wheler, S. Moulder, T. Helgason, S. Li, I. Elias, N. Desai and R. Kurzrock (2013). "Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial." Clin Cancer Res 19(19): 5474-5484.  
Gradishar, W. J., S. Tjulandin, N. Davidson, H. Shaw, N. Desai, P. Bhar, M. Hawkins and J. O'Shaughnessy (2005). "Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer." J Clin Oncol 23(31): 7794-7803. Hallet, J., C. H. Law, M. Cukier, R. Saskin, N. Liu and S. Singh (2015). "Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes." Cancer 121(4): 589-597.  
Hanna, S. C., S. A. Heathcote and W. Y. Kim (2008). "mTOR pathway in renal cell carcinoma."
Expert Rev Anticancer Ther 8(2): 283-292.  
Kennecke, H., M. Rahman, S. Yip, R. Woods, D. Schaeffer and I. Tai (2011). Effect of nabrapamycin versus rapamycin in colorectal cancer cell lines and associations with KRAS and PI3K
mutations. Proceedings of the 47th American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL,, J Clin Oncol Kratz, F. (2008). "Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles." J Control Release 132(2): 171-183. Kremer, P., G. Hartung, U. Bauder-Wust, H. H. Schrenk, A. Wunder, S. Heckl, U. Zillmann and H. Sinn (2002). "Efficacy and tolerability of an aminopterin-albumin conjugate in tumor-bearing rats." Anticancer Drugs 13(6): 615-623.  
Manfredi, G. I., A. Dicitore, G. Gaudenzi, M. Caraglia, L. Persani and G. Vitale (2015). "PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy." Endocrine 48(2): 363-370. Molina, A. M., D. R. Feldman, M. H. Voss, M. S. Ginsberg, M. S. Baum, D. R. Brocks, P. M. Fischer, M. J. Trinos, S. Patil and R. J. Motzer (2011). "Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma." Cancer 118(7): 1868-1876. Novartis-Gleevec (2017). Sutent Prescribing Information. Novartis (2017). Everolimus (Afinitor) Prescribing Information. O'Donnell, A., S. Faivre, H. A. Burris, 3rd, D. Rea, V. Papadimitrakopoulou, N. Shand, H. A. Lane, K. Hazell, U. Zoellner, J. M. Kovarik, C. Brock, S. Jones, E. Raymond and I. Judson (2008). "Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors." J Clin Oncol 26(10): 1588-1595.  
Pfizer (2011). Prescribing Information: TORISEL Kit (temsirolimus) injection, for intravenous infusion only. Pfizer (2011). Rapamune Prescribing Information.  
Pusceddu, S., E. Verzoni, N. Prinzi, A. Mennitto, D. Femia, P. Grassi, L. Concas, C. Vernieri, G. Lo Russo and G. Procopio (2017). "Everolimus treatment for neuroendocrine tumors: latest results and clinical potential." Ther Adv Med Oncol 9(3): 183-188.  
Qi, W. X., Y. J. Huang, Y. Yao, Z. Shen and D. L. Min (2013). "Incidence and risk of treatmentrelated mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a metaanalysis." PLoS One 8(6): e65166.  
Schnitzer, J. E. (1992). "gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis." Am J Physiol 262(1 Pt 2): H246-254. Schnitzer, J. E., P. Oh, B. S. Jacobson and A. M. Dvorak (1995). "Caveolae from luminal plasmalemma of rat lung endothelium: microdomains enriched in caveolin, Ca(2+)-ATPase, and inositol trisphosphate receptor." Proc Natl Acad Sci U S A 92(5): 1759-1763. Sehgal, S. N. (2003). "Sirolimus: its discovery, biological properties, and mechanism of action." Transplant Proc 35(3 Suppl): 7S-14S. Strosberg, J., G. El-Haddad, E. Wolin, A. Hendifar, J. Yao, B. Chasen, E. Mittra, P. L. Kunz, M. H. Kulke, H. Jacene, D. Bushnell, T. M. O'Dorisio, R. P. Baum, H. R. Kulkarni, M. Caplin, R. Lebtahi, T. Hobday, E. Delpassand, E. Van Cutsem, A. Benson, R. Srirajaskanthan, M. Pavel, J. Mora, J. Berlin, E. Grande, N. Reed, E. Seregni, K. Oberg, M. Lopera Sierra, P. Santoro, T. Thevenet, J. L. Erion, P. Ruszniewski, D. Kwekkeboom, E. Krenning and N.-T. Investigators (2017). "Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors." N Engl J Med 376(2): 125-135.  
Strosberg, J. R., R. L. Fine, J. Choi, A. Nasir, D. Coppola, D. T. Chen, J. Helm and L. Kvols (2011). "First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas." Cancer 117(2): 268-275.  
Thompson, L. A., M. Kim, S. D. Wenger and C. L. O'Bryant (2012). "Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors." Ann Pharmacother 46(9): 1212-1219. Trieu, V., S. Ran, L. Volk, A. Stutzman, O. D'Cruz and N. Desai (2009). CNS safety, antitumor activity, and antiangiogenic activity of nab-rapamycin (ABI-009). Proceedings of the 100th American Association for Cancer Research Annual Meeting (AACR), Denver CO, AACR. Yao, J. C., M. Hassan, A. Phan, C. Dagohoy, C. Leary, J. E. Mares, E. K. Abdalla, J. B. Fleming, J. N. Vauthey, A. Rashid and D. B. Evans (2008). "One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States." J Clin Oncol 26(18): 3063-3072. Yao, J. C., M. H. Shah, T. Ito, C. L. Bohas, E. M. Wolin, E. Van Cutsem, T. J. Hobday, T. Okusaka, J. Capdevila, E. G. de Vries, P. Tomassetti, M. E. Pavel, S. Hoosen, T. Haas, J. Lincy, D. Lebwohl, K. Oberg and T. T. S. G. Rad001 in Advanced Neuroendocrine Tumors (2011). "Everolimus for advanced pancreatic neuroendocrine tumors." N Engl J Med 364(6): 514-523. Yuan, R., A. Kay, W. J. Berg and D. Lebwohl (2009). "Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy." J Hematol Oncol 2: 45. Zhou, H., Y. Luo and S. Huang (2010). "Updates of mTOR inhibitors." Anticancer Agents Med Chem 10(7): 571-581.